05-22-2007
New Study Shows Humira Affectively Treats Psoriasis
The Biological drug Humira which is traditionally used to treat rheumatoid arthritis has recently been shown as an affective treatment for psoriasis.
According to Biologicaldrugreport.com, “This is the second Phase III study to show positive results for Humira, a biologic currently approved for rheumatoid arthritis treatment, and Abbott Laboratories said it is going to file during the first six months of this year for U.S. and European regulatory approval for Humira in psoriasis treatment. Two other biologics used to treat rheumatoid arthritis, Amgen Inc.’s Enbrel and Centocor’s Remicade, have already received FDA approval as a treatment for psoriasis.”
In the recent study, 1200 patients suffering from moderate to severe psoriasis were randomly given doses of Humira every second week or a placebo.
The results of the study found that almost 3 quarters of the patients that received Humira doses showed at least 75% improvement over normal signs of the disease after the 4 month treatment cycle.
The results showed that Humira was statistically better at treating psoriasis than the current standard methods used to treat the disease. Humira has a great chance to potentially be approved as a treatment for psoriasis.
























